These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34957309)

  • 1.
    Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
    Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
    J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
    Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
    Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, and
    Choudhari RC; Kaur K; Das A; Jaitak V
    Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
    Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
    Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Rajagopal K; Kalusalingam A; Bharathidasan AR; Sivaprakash A; Shanmugam K; Sundaramoorthy M; Byran G
    Molecules; 2023 May; 28(10):. PubMed ID: 37241915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of marine Streptomyces compounds with selected cancer drug target proteins by in silico molecular docking studies.
    Lankapalli AR; Kannabiran K
    Interdiscip Sci; 2013 Mar; 5(1):37-44. PubMed ID: 23605638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer.
    Suganya J; Radha M; Naorem DL; Nishandhini M
    Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
    Ashtekar SS; Bhatia NM; Bhatia MS
    Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
    Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
    J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Alkyl Triphenylphosphonium Pinostrobin Derivatives as Potent Anti-Breast Cancer Agents.
    Tran TH; Le TH; Nguyen TT; Vong LB; Nguyen MTT; Nguyen NT; Dang PH
    Chem Biodivers; 2024 Jul; 21(7):e202400864. PubMed ID: 38699953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Virtual Drug Discovery Screening Illuminates Campesterol as a Potent Estrogen Receptor Alpha Inhibitor in Breast Cancer.
    Majumder R; Banerjee S; Mandal M; Patra S; Das S; Mandal M
    J Med Chem; 2024 Jun; 67(12):10321-10335. PubMed ID: 38836562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potential inhibitors of HER2 targeting breast cancer-a structure-based drug design approach.
    Singh G; Al-Fahad D; Al-Zrkani MK; Chaudhuri TK; Soni H; Tandon S; Narasimhaji CV; Azam F; Patil R
    J Biomol Struct Dyn; 2024 Sep; 42(15):8184-8201. PubMed ID: 37565730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
    Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine-Derived Compounds as Potential Inhibitors of Hsp90 for Anticancer and Antimicrobial Drug Development: A Comprehensive In Silico Study.
    Ouassaf M; Bourougaa L; Al-Mijalli SH; Abdallah EM; Bhat AR; A Kawsar SM
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.
    Islam S; Amin MA; Rengasamy KRR; Mohiuddin AKM; Mahmud S
    Cancer Med; 2024 Aug; 13(15):e70074. PubMed ID: 39101505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.